title: Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives.
abstract: IMiDs compounds are a class of analogues of thalidomide, with greater immunomodulatory activity and a superior safety profile compared to the parent compound. They show substantial increase in potency and an interesting tolerability profile, primarily due to a decreased incidence of the most severe side effect of thalidomide, i.e. Chemotherapy-Induced Peripheral Neurotoxicity (CIPN). These novel aspects of the IMiDs compounds will be discussed.
authors.affiliation: Medical Department, Celgene S.r.l., Corso Garibaldi 86 - 20121 Milano, Italy.
authors.forename: Sante
authors.initials: S
authors.lastname: Cundari
authors.forename: Guido
authors.initials: G
authors.lastname: Cavaletti
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D006868:Hydrolysis; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000737:chemistry* / Q000378:metabolism; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide